TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07015996: Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 62 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,518,000

Rescue Site Savings

+$1,000,500

Unlock Full NCT07015996 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07015996 Rescue Dossier →